Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 56

1.

Towards irreversible HIV inactivation: stable gp120 binding by nucleophilic antibodies.

Nishiyama Y, Karle S, Mitsuda Y, Taguchi H, Planque S, Salas M, Hanson C, Paul S.

J Mol Recognit. 2006 Sep-Oct;19(5):423-31.

PMID:
16838382
2.

Towards covalent vaccination: improved polyclonal HIV neutralizing antibody response induced by an electrophilic gp120 V3 peptide analog.

Nishiyama Y, Mitsuda Y, Taguchi H, Planque S, Salas M, Hanson CV, Paul S.

J Biol Chem. 2007 Oct 26;282(43):31250-6. Epub 2007 Aug 29.

3.

Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120.

Paul S, Planque S, Zhou YX, Taguchi H, Bhatia G, Karle S, Hanson C, Nishiyama Y.

J Biol Chem. 2003 May 30;278(22):20429-35. Epub 2003 Mar 28.

4.

Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120.

Paul S, Karle S, Planque S, Taguchi H, Salas M, Nishiyama Y, Handy B, Hunter R, Edmundson A, Hanson C.

J Biol Chem. 2004 Sep 17;279(38):39611-9. Epub 2004 Jul 21.

5.

V3 loop truncations in HIV-1 envelope impart resistance to coreceptor inhibitors and enhanced sensitivity to neutralizing antibodies.

Laakso MM, Lee FH, Haggarty B, Agrawal C, Nolan KM, Biscone M, Romano J, Jordan AP, Leslie GJ, Meissner EG, Su L, Hoxie JA, Doms RW.

PLoS Pathog. 2007 Aug 24;3(8):e117.

6.

A comparative immunogenicity study in rabbits of disulfide-stabilized, proteolytically cleaved, soluble trimeric human immunodeficiency virus type 1 gp140, trimeric cleavage-defective gp140 and monomeric gp120.

Beddows S, Franti M, Dey AK, Kirschner M, Iyer SP, Fisch DC, Ketas T, Yuste E, Desrosiers RC, Klasse PJ, Maddon PJ, Olson WC, Moore JP.

Virology. 2007 Apr 10;360(2):329-40. Epub 2006 Nov 28.

7.

Antibodies to the superantigenic site of HIV-1 gp120: hydrolytic and binding activities of the light chain subunit.

Nishiyama Y, Karle S, Planque S, Taguchi H, Paul S.

Mol Immunol. 2007 Apr;44(10):2707-18. Epub 2007 Jan 12.

PMID:
17222909
8.

Neutralizing antibodies decrease the envelope fluidity of HIV-1.

Harada S, Monde K, Tanaka Y, Kimura T, Maeda Y, Yusa K.

Virology. 2008 Jan 5;370(1):142-50. Epub 2007 Sep 27.

9.

A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism.

Dimitrov JD, Planchais C, Scheel T, Ohayon D, Mesnage S, Berek C, Kaveri SV, Lacroix-Desmazes S.

J Biol Chem. 2014 Jun 20;289(25):17767-79. doi: 10.1074/jbc.M114.556266. Epub 2014 May 6.

10.

Efficient capture of antibody neutralized HIV-1 by cells expressing DC-SIGN and transfer to CD4+ T lymphocytes.

van Montfort T, Nabatov AA, Geijtenbeek TB, Pollakis G, Paxton WA.

J Immunol. 2007 Mar 1;178(5):3177-85.

11.

Journal club. A structural biologist has great expectations for llamas' small antibodies.

Hwang WC.

Nature. 2009 May 21;459(7245):303. doi: 10.1038/459303e. No abstract available.

PMID:
19458671
12.

The presence of antibodies recognizing a peptide derived from the second conserved region of HIV-1 gp120 correlates with non-progressive HIV infection.

Djordjevic A, Veljkovic M, Antoni S, Sakarellos-Daitsiotis M, Krikorian D, Zevgiti S, Dietrich U, Veljkovic N, Branch DR.

Curr HIV Res. 2007 Sep;5(5):443-8.

PMID:
17896963
13.

Resistance of HIV-1 to the broadly HIV-1-neutralizing, anti-carbohydrate antibody 2G12.

Huskens D, Van Laethem K, Vermeire K, Balzarini J, Schols D.

Virology. 2007 Apr 10;360(2):294-304. Epub 2006 Nov 21.

14.

Changes in HIV-specific antibody responses and neutralization titers in patients under ART.

Falkensammer B, Freissmuth D, Hübner L, Speth C, Dierich MP, Stoiber H.

Front Biosci. 2007 Jan 1;12:2148-58.

PMID:
17127452
15.

Is human immunodeficiency virus RNA load composed of neutralized immune complexes?

Dianzani F, Antonelli G, Riva E, Turriziani O, Antonelli L, Tyring S, Carrasco DA, Lee H, Nguyen D, Pan J, Poast J, Cloyd M, Baron S.

J Infect Dis. 2002 Apr 15;185(8):1051-4. Epub 2002 Apr 1.

PMID:
11930314
16.

Coadsorption of HIV-1 p24 and gp120 proteins to surfactant-free anionic PLA nanoparticles preserves antigenicity and immunogenicity.

Lamalle-Bernard D, Munier S, Compagnon C, Charles MH, Kalyanaraman VS, Delair T, Verrier B, Ataman-Onal Y.

J Control Release. 2006 Sep 28;115(1):57-67. Epub 2006 Jul 13.

PMID:
16919350
18.

Prospects for immunotherapeutic proteolytic antibodies.

Zhou YX, Karle S, Taguchi H, Planque S, Nishiyama Y, Paul S.

J Immunol Methods. 2002 Nov 1;269(1-2):257-68. Review.

PMID:
12379366
19.

Antibody binding is a dominant determinant of the efficiency of human immunodeficiency virus type 1 neutralization.

Yang X, Lipchina I, Cocklin S, Chaiken I, Sodroski J.

J Virol. 2006 Nov;80(22):11404-8. Epub 2006 Sep 6.

20.

Supplemental Content

Support Center